These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 24706226)

  • 21. The John Barnwell Lecture. The chemotherapy of bacterial respiratory infections.
    Crofton J
    Am Rev Respir Dis; 1970 Jun; 101(6):841-59. PubMed ID: 4914352
    [No Abstract]   [Full Text] [Related]  

  • 22. Aerosolized antimicrobial therapy in acutely ill patients.
    Wood GC; Boucher BA
    Pharmacotherapy; 2000 Feb; 20(2):166-81. PubMed ID: 10678295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of microbiological control in the choice of antibacterial therapy of respiratory infection in surgical patients during the postoperative period].
    Bekbergenov BM; Gel'fand BR; Speranskaia ON; Navashin PS
    Antibiot Khimioter; 1989 Jan; 34(1):60-4. PubMed ID: 2730217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Etiopathogenic and therapeutic aspects of chronic respiratory infection in cystic fibrosis].
    Caramia G; Gagliardini R; Rocchi AL; Palumbo P
    Minerva Pediatr; 1986 Jul; 38(13-14):569-78. PubMed ID: 3528799
    [No Abstract]   [Full Text] [Related]  

  • 25. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections.
    Saha T; Lyons N; Yue Yung DB; Quiñones-Mateu ME; Pletzer D; Das SC
    Eur J Pharm Biopharm; 2024 Feb; 195():114170. PubMed ID: 38128743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the in vitro activity of and pathogen responses to sparfloxacin with those of other agents in the treatment of respiratory tract, urinary tract, and skin and skin-structure infections.
    Dowzicky M; Nadler H; Dorr MB; Acusta A; Talbot GH
    Clin Ther; 1999 May; 21(5):790-805; discussion 789. PubMed ID: 10397375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of new quinolones in the treatment of respiratory tract infections.
    Finch RG
    Drugs; 1995; 49 Suppl 2():144-51. PubMed ID: 8549285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of ofloxacin in lower respiratory tract infections.
    Kobayashi H
    Infection; 1986; 14 Suppl 4():S279-82. PubMed ID: 3469163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of clinical trials with fluoroquinolones with an emphasis on new agents.
    Blondeau JM
    Expert Opin Investig Drugs; 2000 Feb; 9(2):383-413. PubMed ID: 11060684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
    Momméja-Marin H; Carbon C
    Drugs; 1999 Jun; 57(6):851-3. PubMed ID: 10400400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.
    Pechère JC; Gootz TD
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):405-12. PubMed ID: 9758283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chinese expert consensus on the management of lower respiratory tract infections of
    Pulmonary Infection Assembly of Chinese Thoracic Society
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):739-752. PubMed ID: 35927044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Odoriferous Therapy: A Review Identifying Essential Oils against Pathogens of the Respiratory Tract.
    Leigh-de Rapper S; van Vuuren SF
    Chem Biodivers; 2020 Jun; 17(6):e2000062. PubMed ID: 32207224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic approach to respiratory infections in lung transplantation.
    Clajus C; Blasi F; Welte T; Greer M; Fuehner T; Mantero M
    Pulm Pharmacol Ther; 2015 Jun; 32():149-54. PubMed ID: 25038552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary and cardiac infections in athletes.
    Kruse RJ; Cantor CL
    Clin Sports Med; 2007 Jul; 26(3):361-82. PubMed ID: 17826189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial treatment of acute bacterial pulmonary infections. A statement by the Committee on therapy.
    Am Rev Respir Dis; 1968 Oct; 98(4):732-6. PubMed ID: 5677162
    [No Abstract]   [Full Text] [Related]  

  • 37. Antimicrobial therapy for lower respiratory tract infections.
    van den Broek PJ
    Pharm Weekbl Sci; 1989 Aug; 11(4):118-20. PubMed ID: 2677982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection.
    Oosterheert JJ; van Loon AM; Schuurman R; Hoepelman AI; Hak E; Thijsen S; Nossent G; Schneider MM; Hustinx WM; Bonten MJ
    Clin Infect Dis; 2005 Nov; 41(10):1438-44. PubMed ID: 16231254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Other communal respiratory pathogens and new fluoroquinolones].
    Cantón R; Loza E; Valdezate S; Baquero F
    Enferm Infecc Microbiol Clin; 1998 Dec; 16 Suppl 2():12-21; discussion 47-52. PubMed ID: 10344094
    [No Abstract]   [Full Text] [Related]  

  • 40. Newer fluoroquinolones and the management of respiratory tract infections.
    Karchmer AW
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S15. PubMed ID: 10984322
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.